Claims for Patent: 11,633,478

Summary for Patent: 11,633,478

Title:	Compositions and kits for Omeprazole suspension
Abstract:	Disclosed herein are liquid diluents, formulations, and kits for preparing reconstituted suspensions of a proton pump inhibitor (e.g., omeprazole). The present disclosure also provides formulations for liquid diluents that do not have a tendency for gel formation following exposure to freeze-thaw cycles.
Inventor(s):	Zeus Pendon, Steven Dinh
Assignee:	Azurity Pharmaceuticals Inc
Application Number:	US17/576,496
Patent Claims:	1. A freeze-thaw stable diluent for reconstituting a proton pump inhibitor, comprising: poloxamer, sodium carboxymethylcellulose (CMC), sodium bicarbonate, a buffering agent, simethicone emulsion, a preservative, a sweetener, water, and optionally a flavoring agent and a coloring agent, wherein the liquid diluent is stable for at least 30 days at 5±3° C. and is resistant to gel formation for at least one freeze-thaw cycle. 2. The liquid diluent of claim 1, consisting essentially of: 1.0%-4.0% w/v poloxamer, wherein the poloxamer is poloxamer 188; 1.0%-2.0% w/v sodium carboxymethylcellulose (CMC); 8.0%-8.8% w/v sodium bicarbonate; 0.5%-1.5% w/v sodium citrate; 0.1%-0.3% w/v simethicone emulsion; 0.35%-3.5% w/v sweetener; 0.4%-0.6% w/v preservative; and water; wherein the liquid diluent is stable for at least 30 days at 5±3° C. and is resistant to gel formation for at least one freeze-thaw cycle. 3. The liquid diluent of claim 1, wherein the poloxamer is present in the liquid diluent at 1% w/v, 2% w/v, or 4% w/v. 4. The liquid diluent of claim 1, wherein the sodium bicarbonate is present in the liquid diluent at 8.4% w/v. 5. The liquid diluent of claim 1, wherein the liquid diluent comprises about 1% w/v of a citrate salt. 6. The liquid diluent of claim 1, wherein the simethicone emulsion is present in the liquid diluent at 0.15% w/v. 7. The liquid diluent of claim 1, wherein the sweetener comprises 70% sorbitol solution and sucralose. 8. The liquid diluent of claim 7, wherein the 70% sorbitol solution is present in the liquid diluent at 2.5% w/v and the sucralose is present in the liquid diluent at 0.4 w/v. 9. The liquid diluent of claim 1, wherein the liquid diluent is stable for at least 30 days at 25±5° C. 10. The liquid diluent of claim 1, wherein the preservative is benzyl alcohol. 11. The liquid diluent of claim 10, wherein the liquid diluent comprises about 0.5% w/v of benzyl alcohol. 12. The liquid diluent of claim 1, wherein the preservative is a paraben or a mixture of parabens. 13. The liquid diluent of claim 1, wherein the sodium bicarbonate is present in the liquid diluent at 4.0%-20% w/v. 14. The liquid diluent of claim 1, wherein the sodium bicarbonate is present at 10% w/v to 20% w/v in the liquid diluent. 15. The liquid diluent of claim 1, wherein the poloxamer is poloxamer 188. 16. The liquid diluent of claim 1, wherein the preservative comprises benzyl alcohol, ascorbic acid, ascorbyl palmitate, BHA, BHT, citric acid, sodium benzoate, benzoic acid, sodium bisulfate, sodium metabisulfite, sodium sulfite, parabens, potassium sorbate, vanillin, any pharmaceutically acceptable salts thereof, or any combination thereof. 17. The liquid diluent of claim 1, wherein the buffering agent comprises citric acid, sodium citrate, sodium tartrate, sodium acetate, sodium carbonate, phosphoric acid, sodium polyphosphate, potassium polyphosphate, sodium pyrophosphate, potassium pyrophosphate, disodium hydrogen phosphate, dipotassium hydrogen phosphate, trisodium phosphate, tripotassium phosphate, sodium acetate, potassium metaphosphate, magnesium carbonate, calcium acetate, calcium glycerophosphate, lactate, calcium carbonate, or any combination thereof. 18. The liquid diluent of claim 1, consisting essentially of: 0.5%-4.0% w/v poloxamer; 1.0%-5.0% w/v of a suspending agent, wherein the suspending agent is (i) sodium carboxymethylcellulose (CMC) or (ii) a combination of sodium CMC and microcrystalline cellulose; 4.0%-20% w/v of sodium bicarbonate; 0.1%-0.3% w/v of simethicone emulsion; 0.2%-1.2% w/v of a preservative; water; a buffering agent, wherein the buffering agent maintains a pH of 8 to 9.5; a sweetener; optionally one or more selected from a coloring agent and a flavoring agent; and wherein the liquid diluent is stable for at least 30 days at 5±3° C. and is resistant to gel formation for at least one freeze-thaw cycle. 19. The liquid diluent of claim 1, wherein the proton pump inhibitor is omeprazole, esomeprazole, lansoprazole, rabeprazole, pantoprazole, or dexlansoprazole. 20. The liquid diluent of claim 19, wherein the proton pump inhibitor is lansoprazole.